A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Inclusion Criteria

• •Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb
• •Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.
• •Patients may have to have tumor biopsy before and after treatment.